Effects of Risperidone on Aberrant Behavior of Persons With Developmental Disabilities: I. A Double-Blind Crossover Study Using Multiple Measures

Zarcone, Jennifer R.; Hellings, Jessica A.; Crandall, Kurt; Reese, R. Matthew; Marquis, Janet; Fleming, Kandace; Shores, Richard E.; Williams, Dean C.; Schroeder, Stephen R.

doi:10.1352/0895-8017(2001)106<0525:eoroab>2.0.co;2

Cited by 97 publications

(65 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A series of small N experiments illustrates the importance of these individual differences in response to risperidone. As part of an analysis of a subset of participants in a larger RCT, 66 70 concluded that weight gain ranged from -0.2 kg (ziprazidone) to 4.3 kg (olanzipine.) Such data are incomplete as future long-term studies may reveal other negative side effects that short-term RCTs do not reveal and that are currently unknown.…”

Section: Autism Spectrum Disordersmentioning

confidence: 99%

Treatment of Psychopathology in People with Intellectual and other Disabilities

Sturmey

2012

Can J Psychiatry

View full text Add to dashboard Cite

Objective: To review the psychosocial, pharmacological, and other treatments of psychopathology in people with intellectual disabilities (IDs), autism, and other developmental disabilities (DDs).Method: Systematic reviews and meta-analyses of psychosocial, pharmacological, and other treatments for people with DDs are reviewed. Results:There is strong evidence for applied behaviour analysis (ABA) and other behavioural treatments of some forms of psychopathology. There is little good evidence to support the effectiveness of cognitive-behavioural therapy, cognitive therapy, sensory interventions, and other forms of psychosocial interventions. Recently, more randomized controlled trials (RCTs) of psychopharmacology have been published, especially with people with autism spectrum disorders. Most RCTs were for externalizing behaviour problems, rather than for psychopathology. These RCTs offer only preliminary support for the effectiveness of pharmacotherapy. No evidence was found for the effectiveness of other biological treatments. Conclusions:Current research supports the use of ABA and other behavioural interventions for some forms of psychopathology. Evidence for the effectiveness of other interventions is limited or absent.

show abstract

Section: Autism Spectrum Disordersmentioning

confidence: 99%

Treatment of Psychopathology in People with Intellectual and other Disabilities

Sturmey

2012

Can J Psychiatry

View full text Add to dashboard Cite

show abstract

“…Numerous clinical studies document how atypical antipsychotics such as risperidone successfully reduce aggressive behavior in adolescent, middle-aged and elderly patients with varying diagnoses such as depression, schizophrenia, dementia and mental retardation, and post-traumatic stress disorder (Czobor et al 1995;Buckley et al 1997;De Deyn et al 1999;Keck et al 2000;Buitelaar et al 2001;Zarcone et al 2001). The antagonistic action of risperidone at 5-HT 2A receptors is more predominant than its antagonism of D 2 receptors (Schotte et al 1996).…”

Section: -Ht 2 Receptor Familymentioning

confidence: 99%

Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and ?-aminobutyric acid systems

et al. 2002

View full text Add to dashboard Cite

(1) The preclinical focus on the behavioral characteristics and determinants of intense aggression promises to be most relevant to the clinical distinction between the proposed impulsive-reactive-hostile-affective subtypes of human aggression and the controlled-proactive-instrumental-predatory subtypes of aggression. The neural circuits for many types of human and animal aggression critically involve serotonin, dopamine and gamma-aminobutyric acid (GABA) and specific receptor subtypes. (2) The dynamic changes in frontal cortical serotonin that are triggered by engaging in aggressive behavior imply that serotonergic drug effects are largely determined by the functional state of the receptors at the time of drug treatment. Of the numerous 5-HT receptors currently identified, the 5-HT(1B) receptors offer a promising target for reducing impulsive aggressive behavior, particularly if the action can be limited to sites in the central nervous system. (3) Aggressive confrontations are salient stressors, both for the aggressor as well as the victim of aggression, that are accompanied by activation of the mesocorticolimbic but not the striatal dopamine system. Dopaminergic manipulations, particularly targeting the D(2) receptor family, can influence aggressive behavior in animals and human patients, suggesting that mesocorticolimbic dopamine may have important enabling or permissive functions. (4) GABA is critical in the neurochemical control of aggressive behavior as evidenced by studies that directly modify GABAergic neurotransmission and neurochemical studies that correlate GABA measurements with aggressive behavioral responses in several animal species. The GABA(A) receptor complex is a mechanism through which certain benzodiazepines and alcohol enhance and inhibit aggressive behaviors. Social and pharmacological experiences decisively determine the effects of GABAergic positive modulators on aggression.

show abstract

“…Risperidone has been studied extensively in managing disruptive behavior disorders in children and adolescents (Aman et al 2002;Buitelaar 2000;Findling et al 1997Findling et al , 2000McDougle et al 1997;Nicolson et al 1998;Santosh and Baird 1999;Snyder et al 2002;Turgay et al 2002;Van Bellinghen and De Troch 2001). A handful of case reports and a small double-blind study suggest that risperidone is beneficial for managing aggression in adult patients with pervasive developmental disorders, such as autism, and varying degrees of intellectual disability (Cohen et al 1998;Dartnall et al 1999;McDougle et al 1995;Purdon et al 1994;Simon et al 1996;Vanden Borre et al 1993;Zarcone et al 2001).…”

Section: Introductionmentioning

confidence: 99%